Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Want to see TSE:CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
C$2.06
-C$0.08(-4.06%)
At close: 4:00 PM EST
C$2.06
-C$0.08(-4.06%)
Day’s Range― - ―
52-Week RangeC$1.23 - C$2.33
Previous CloseN/A
Volume34.34K
Average Volume (3M)136.50K
Market Cap
C$167.81M
Enterprise ValueC$161.51M
Total Cash (Recent Filing)C$27.67M
Total Debt (Recent Filing)C$116.41K
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding111,872,086
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.84Price Target Upside474.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageExtremely low debt (debt-to-equity ~0.005) materially reduces refinancing and interest burden risk. For a clinical-stage biotech this durable strength preserves financial flexibility to pursue trials, partnerships, or licensing without immediate solvency pressure, extending strategic optionality.
Focused Clinical-stage PipelineA concentrated R&D focus on CardiolRx and CRD-38 targets anti-inflammatory and anti-fibrotic cardiovascular therapies, addressing structural unmet needs. This clear product focus supports coherent trial programs and partnership appeal, which are durable advantages if clinical data prove supportive.
Improving Cash Outflow TrajectoryManagement has begun narrowing cash outflows versus prior periods, indicating improving capital efficiency. A sustained reduction in burn rate would extend runway, lower near-term dilution risk, and make it easier to execute multi-phase clinical programs without frequent emergency financing.
Bears Say
Pre-revenue With Sizable LossesNo commercial revenue and sustained multi‑million dollar net losses mean the company depends on external capital until approval/commercialization. This structural profile increases execution risk, makes operating leverage weak, and heightens reliance on trial success to generate durable cash flows.
Heavy Cash Burn And Funding RiskPersistently negative operating and free cash flow (~-$24M TTM) requires ongoing financing to fund R&D and trials. That structural cash-gap increases dilution risk, can delay programs if markets tighten, and makes long-term planning dependent on successful capital raises or material partnerships.
Declining Equity And Negative ROEDeclining shareholders' equity and negative ROE signal ongoing value erosion from operations. Over the medium term this limits internally generated capital, undermines resilience to shocks, and increases reliance on external funding, highlighting execution and profitability challenges that persist absent commercial revenue.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.23 and its highest was C$2.33 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$167.81M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 66 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 111,872,086 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$11.84 (474.94% Upside)
C$11.84 (474.94% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-229.16%
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$11.84
▲(474.94% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---